A prospective imaging study of131I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: Preliminary report

S. Lastoria, P. D'amico, L. Mansi, G. G. Giordano, R. Rossiello, J. Schlom, E. Pace, N. Panza, G. Pacilio, M. Salvatore

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty patients with known ovarian cancer have been investigated in this pilot study to verify the clinical usefulness of radioimaging using the B72.3 monoclonal antibody labelled with iodine-131. No adverse reactions occurred after intravenous injection of B72.3 MoAb. The radioimaging results were compared with those obtained with other diagnostic methods, including computed X-ray tomography and ultrasound. A sensitivity of 85% in the detection of primary ovarian cancers and collections of ascites, and of 84% in the detection of abdominal and extraperitoneal metastases has been demonstrated using this radioiodinated antibody in vivo. No false localization occurred. Immunohistochemical studies showed no cross-reactions between B72.3 MoAb and mesothelial cells, confirming the high specificity of binding between B72.3 MoAb and neoplastic cells in ascites. Negligible uptake of radiolabelled B72.3 MoAb has been demonstrated in the unaffected ovary. The major advantage of using this monoclonal antibody is related to the expression of a recognized antigen (called TAG 72) in mucinous, serous and in differentiated adenocarcinomas of the ovary.

Original languageEnglish
Pages (from-to)347-356
Number of pages10
JournalNuclear Medicine Communications
Volume9
Issue number5
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'A prospective imaging study of<sup>131</sup>I-B72.3 monoclonal antibody in patients with epithelial ovarian cancer: Preliminary report'. Together they form a unique fingerprint.

Cite this